Sanofi GCVRZ 深 沪
等待开盘 02-07 09:30:00 美东时间
--
0.000
NaN.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 --
- 总市值 0
- 52周最高 0.00
- 市盈率 静 --
- 换手率 NaN.00%
- 52周最低 0.00
- 委 比 0.00%
- 总股本 --
- 历史最高 0.00
- 量 比 0
- 振 幅 NaN.00%
- 历史最低 0.00
- 每 手 1
- 风险率
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Earnings Outlook For Regeneron Pharmaceuticals
Regeneron Pharmaceuticals (NASDAQ:REGN) will release its quarterly earnings rep...
01-29 22:01
Earnings Scheduled For January 29, 2026
Companies Reporting Before The Bell • MOGU (NYSE:MOGU) is estimated to report e...
01-29 19:11
Sanofi Q4 Sales $13.159B Miss $13.410B Estimate
Sanofi (NASDAQ:SNY) reported quarterly sales of $13.159 billion which missed the analyst consensus estimate of $13.410 billion by 1.87 percent. This is a 16.71 percent increase over sales of $11.275 billion the same
01-29 14:39
Earnings Preview: Sanofi
Sanofi (NASDAQ:SNY) is preparing to release its quarterly earnings on Thursday,...
01-28 23:02
UBS Downgrades Sanofi to Neutral
UBS analyst Matthew Weston downgrades Sanofi (NASDAQ:SNY) from Buy to Neutral.
01-16 21:39
Penumbra, ImmunityBio, Calix, Matson And Other Big Stocks Moving Higher On Thursday
U.S. stocks were higher, with the Dow Jones index gaining more than 300 points ...
01-15 23:28
FDA Shows Caution, Delays Trump-Backed Fast-Track Drugs Over Risks
FDA delayed fast-track reviews for multiple drugs after safety and efficacy concerns, including adverse events and a reported patient death.
01-15 21:26
France's La Lettre Reported Sanofi Preparing Revised Bid For Ocular Therapeutics
https://www.lalettre.fr/fr/entreprises_sante/2026/01/15/sanofi-convoite-la-biotech-americaine-ocular-therapeutix,110601230-eve
01-15 19:45
Regeneron Just Moved From Underperform To Buy - Here's Why
Could the tide be turning for Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) after a surprising shift in analyst sentiment?
01-08 05:18
FDA Flags Liver Injury Risk In Sanofi's Rejected Multiple Sclerosis Drug
The FDA rejected Sanofi's MS drug tolebrutinib, citing liver injury risks, unclear benefits, and trial data that failed to show a favorable benefit-risk balance for any patient group.
01-06 21:54
